Contributing factors to health‐related quality of life in multiple sclerosis by Biernacki, Tamás et al.
Brain and Behavior. 2019;9:e01466.	 	 	 | 	1 of 9
https://doi.org/10.1002/brb3.1466
wileyonlinelibrary.com/journal/brb3
1  | INTRODUC TION
Multiple sclerosis (MS) is one of the most common debilitating, pro‐
gressive neuroinflammatory disorders. Most often affects young 
and middle‐aged adults in their most productive lifetime increasing 
the enormous financial burden of the disease (Confavreux, Aimard, 
& Devic, 1980; Zsiros et al., 2014). It affects patients' life in many 
aspects. As the disease progresses, some of the exacerbations 
heal with residual symptoms, thus people with MS (PwMS) are 
forced to live with more and more impairments and restrictions to 
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Abstract
Background: Health‐related quality of life (HRQoL) is lower in people with multiple 
sclerosis (PwMS) compared to the healthy population, psychological symptoms ac‐
companying multiple sclerosis (MS) have a serious impact on the HRQoL of PwMS. 
Data regarding the subject, however, remain conflicting.
Objectives: To evaluate the patients' sociodemographic attributes, education, fa‐
tigue, depression, and cognitive impairment level of impact on the HRQoL for the 
whole cohort as well as comparing the sexes.
Materials and Methods: Three hundred and twenty‐two relapse‐remitting MS pa‐
tients filled out the Fatigue Impact Scale (FIS), Beck Depression Inventory (BDI), MS 
Quality	of	Life‐54	(MSQoL‐54)	questionnaires,	cognitive	impairment	were	identified	
using Brief International Cognitive Assessment for MS (BICAMS) test. The patients' 
data were acquired from our clinic's MS registry or from patients' files.
Results: Depression and fatigue were found to have the most ubiquitous and robust 
effect	on	the	overall	and	any	given	subdivision	of	the	HRQoL	composite.	Other	fac‐
tors had a slight effect on some of the subscales when the whole cohort was evalu‐
ated. When the genders were compared, differences were found on 10 domains.
Conclusion: Psychopathological symptoms have a more powerful influence on the 
HRQoL of MS patients than physical impairment, also these symptoms influence 
men's and women's HRQoL with different power. This invokes the need for complex 
and	personalized	care	in	the	treatment	of	PwMS.	Ours	is	the	first	study	to	show	a	
difference between the sexes in this regard.
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their everyday lifestyle. As expected, several studies have shown 
the health‐related quality of life (HRQoL) to be affected in PwMS 
compared with the general population. However, when compared 
to other autoimmune conditions (namely rheumatoid arthritis and 
inflammatory bowel disease), PwMS have the lowest perceived 
HRQoL (Rudick, Miller, Clough, Gragg, & Farmer, 1992). Various fac‐
tors have been identified over the years by several authors to have 
an influence on the HRQoL. Lower household income, higher EDSS 
score, lower score on the 9‐hole‐peg test, weaker coping capacity, 
and a more debilitating, more progressive disease course have been 
all linked to a lower HRQoL, and lower HRQoL has been shown to 
foreshadow worse survival in PwMS (Ruet et al., 2013; Lanzillo et al., 
2016; Kurtzke, 1983; Solaro, Gamberini, & Masuccio, 2018).
In the past two decades, it was revealed that most PwMS have 
cognitive and psychological symptoms as well as physical ones and 
that these symptoms can develop at any stage of the disease (Glanz et 
al., 2007; Amato et al., 2012). The lifetime prevalence of depression 
in	PwMS	is	about	50%;	43%–70%	suffer	from	cognitive	impairment	
(CI) and fatigue turned out to be the most common symptom of the 
disease,	with	a	prevalence	rate	over	90%	(Ben	Ari	Shevil,	Johansson,	
Ytterberg, & von Bergstrom, 2014; Chiaravalloti & DeLuca, 2008). In 
recent years, several evaluations concluded that these psychologi‐
cal symptoms have a serious impact on the HRQoL independently 
from the patients' physical state. CI was shown to be one of the 
most crucial factors in patients becoming unemployed and leading to 
several other serious burdens (Langdon, 2011). Fatigue and depres‐
sion were both shown to be individual factors that heavily worsen 
the HRQoL of PwMS in almost all domains of life (Benedict et al., 
2005).	 Furthermore,	 some	 comprehensive	 assessments	 indicated	
that these psychological aspects of the disease play a greater role in 
determining the HRQoL of PwMS than physical state and other (clin‐
ical,	social,	and	demographic)	characteristics	(Benedict	et	al.,	2005).	
While the merit of the above‐mentioned studies is unquestionable, 
the independent contribution of various cognitive dysfunction and 
clinical disability to the quality of life is only rarely investigated.
Thus, the aims of our study were to:
1. Explore the effect of the sociodemographic and clinical as‐
pects (age, education, sex, and disease duration), as well as 
the psychological aspects (fatigue, depression, and CI) of MS 
on the patients' HRQoL.
2. To determine the most important contributor(s) to MS patients' 
HRQoL.
3. To further explore the potential differences between the sexes, 
considering that there are known differences between man and 
women regarding prognosis and symptoms.
2  | MATERIAL S AND METHODS
2.1 | Participants and data collection
We have involved a total of 322 patients in the present study. 
The patients were recruited from the MS outpatient clinic of the 
Department of Neurology of the University of Szeged, the Jahn 
Ferenc Dél‐Pest Hospital of Budapest, and the Markhot Ferenc 
Teaching Hospital of Eger. The study was approved by the Ethics 
Committee of the Faculty of Medicine, University of Szeged 
(207/2015‐SZTE).	All	participants	gave	their	written	informed	con‐
sent in accordance with the Declaration of Helsinki.
Inclusion criteria were (a) informed consent, (b) a definitive MS 
diagnosis according to the revised McDonald criteria (2011), (c) re‐
lapsing–remitting (RRMS—not active, treated patients) or clinically 
isolated syndrome (CIS—not active, not treated) disease course, (d) 
age 18 years or older, (e) native language was Hungarian, (f) the pa‐
tients were in remission and did not receive steroid therapy for at 
least 30 days previous to the evaluation, (g) an Expanded Disability 
Status	Scale	(EDSS)	score	between	0	and	6.5.
Exclusion criteria were: (a) any substance use, which may inter‐
fere with cognitive abilities or psychometric testing, (b) history of 
chronic alcoholism, (c) any concomitant or previous physical or psy‐
chiatric disorder other than MS that could affect the results of cog‐
nitive and/or psychiatric testing, or could affect the patients' mood 
with the exception of depression, (d) any neurological disorder other 
than MS that could influence the result of the administered psycho‐
metric tests, (e) primary‐progressive (PPMS) or secondary progres‐
sive (SPMS) disease course.
The sociodemographic and clinical data of the enrolled patients 
were acquired from the multiple sclerosis registry of the Department 
of Neurology of the University of Szeged if available (Bencsik et al., 
2017). For patients who were not yet in the database or were re‐
cruited from one of the other MS outpatient clinics, the data were 
obtained from the patient documentation delivered by the patient's 
attending physician.
2.2 | Physical disability
Physical disability was measured by the EDSS score (Kurtzke, 1983). 
In each case, the score was determined by the patient's respective 
neurologist specialist at the time of enrollment.
2.3 | Neuropsychiatric tests administered
2.3.1 | Cognitive impairment
All 322 patients have been evaluated with the validated Hungarian 
version of the Brief International Cognitive Assessment for MS 
(BICAMS) test, which is a rapidly administered screening tool with 
high sensitivity and specificity for the detection of cognitive impair‐
ment	in	MS	patients	(Sandi	et	al.,	2015).	It	consists	of	three	subtests,	
namely the orally administered version of the Symbol Digit Modalities 
Test	(SDMT),	the	first	5	immediate	recall	trial	of	the	California	Verbal	
Learning Test‐II (CVLT‐II), and the first 3 immediate recall trial of the 
Brief Visuospatial Memory Test—Revised (BVMT‐R; Langdon et al., 
2012). We considered a patient cognitively impaired if he/she had 
abnormal scores on at least one of the three tests administered, a 
criterion proposed by Dusankova et al. in 2012 (Dusankova, Kalincik, 
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Havrdova, & Benedict, 2012). A score on a given test was considered 
abnormal if it fell outside of the predefined normal values of said 
test.
2.3.2 | Mood
The patients' mood was evaluated by the Beck Depression Inventory 
II (BDI‐II) questionnaire validated for Hungarian (Beck, Steer, & 
Brown, 1996). A patient was considered having depressive symp‐
toms if scored at least 13 points on the test, which is in accordance 
with the standard cutoff point for this test (Beck et al., 1996).
2.3.3 | Fatigue
Fatigue was assessed by the use of the Hungarian version of the 
Fatigue Impact Scale (FIS) questionnaire (Losonczi et al., 2011). It 
consists of 40 items, each of which is scored from 0 (indicating no 
problem) to 4 (indicating a severe problem), providing a final scoring 
scale from 0 to 160. The three internal subscales of the survey exam‐
ine the physical, the social, and the cognitive aspects of fatigue sepa‐
rately. Scoring higher means fatigue is more significantly affecting a 
patient's life. For example, someone with a score of 80 is affected 
by fatigue more than someone with a score of 20. As there is no 
well‐established cutoff score for this test, we considered a patient 
to have been burdened by fatigue if one scored at least 40 points on 
the FIS questionnaire.
2.3.4 | Health‐Related Quality of Life
Of	the	many	tools	available	to	measure	HRQoL	in	MS,	we	used	the	
MSQoL‐54	 questionnaire's	 Hungarian	 validated	 version	 (Fuvesi	 et	
al., 2008). This tool was specifically designed for patients suffering 
from MS by expanding the SF‐36 survey. The questionnaire consists 
of 36 general questions and 18 MS specific ones, in total conceiving 
a	54‐item	instrument	that	contains	12	internal	subscales,	two	single‐
item measures along with two additional summary scores. We used 
the	MSQoL‐54	 survey	because	 it	 is	 a	 very	detailed	questionnaire;	
its basis, the SF‐36 survey is widely used in healthy individuals as 
well, its results are independent of the assessed population and the 
expanded questionnaire is very sensitive to problems presenting in 
patients with MS.
2.4 | Statistical analysis
The most common approach to identify the impact of certain vari‐
ables on an independent variable is the various forms of multi‐
variate regressions. However, this approach might be misleading 
especially in those circumstances when predictors are not in‐
dependent. This is especially true for the to be examined clini‐
cal and cognitive disability. Hence, in order to determine a given 
variable's impact on the evaluated subscale of HRQoL, we utilized 
the model‐free, partial least squares regression (PLS) analysis. PLS 
successively extracts latent (Toth et al., 2017) variables from the 
dependent variables and the predictors in such a way that covari‐
ance between the factors and loadings is maximized. With this ap‐
proach, PLS reduces the dimensionality of the data by providing 
a weighted linear combination of X variables to form orthogonal 
components that predict the dependent variable. In our analysis, 
the	 dependent	 variables	 were	 the	 subscales	 of	 the	 MSQoL‐54	
questionnaire and the preditors were the scores describing the 
clinical and cognitive disability. The statistical inference on the 
significance of the latent variable was carried out by permutation 
tests	on	the	singular	values	of	the	decomposition	(5,000	permuta‐
tions). We regarded the parameter to have an impact on the given 
subscale if the variable importance of projection (VIP) score was 
≥1	(Wold,	Johansson,	&	Cocchi,	1994).	The	greater	the	score,	the	
more important a given variable is to the model. Variables with 
VIP scores <1 are less important and are usually good candidates 
to be omitted from the model. To evaluate any differences regard‐
ing clinical and sociodemographic variables, we used one‐way 
ANOVA	and	Fisher's	exact	test.
3  | RESULTS
In	the	present	study,	a	total	of	322	patients,	102	(31.6%)	men,	and	
220	 (68.4%)	 women	 were	 involved.	 Of	 the	 participants	 enrolled,	
151	(46.9%)	spent	12	or	fewer	years	studying,	and	171	(53.1%)	had	
been educated for more than 12 years. The mean age of our cohort 
was 43 ± 11.90 (Range: 21–69) years. Mean disease duration was 
12.5	±	8.0	(Range:	1–45)	years.	The	average	EDSS	score	of	the	pa‐
tients	was	1.95	±	1.60	(Range:	0–6.5)	points.	Cognitive	impairment	
was	present	 in	164	 (50.9%)	of	our	 subjects.	The	prevalence	of	 fa‐
tigue	was	52.2%	(168	patients),	while	the	prevalence	of	depression	
was	27.0%	(87	patients;	Table	1).
Regarding the comparison of the sexes, we only found a signifi‐
cant	difference	in	the	rate	of	CI;	it	was	present	in	63.7%	of	the	men	
(65	patients),	while	45.0%	of	women	(99	patients;	p < .002; Table 2).
We evaluated all of the examined attributes' impact on all of the 
14 subscales separately, both for the whole cohort and for men and 
women independently. Regarding the whole population, depression 
TA B L E  1   The sociodemographic characteristics of our cohort
Sociodemographic data of the cohort
Age at enrollment (min, max, SD) [years] 42.96 (21, 69, 11.88)
EDSS (min, max, SD) [points] 1.95	(0,	6.5,	1.57)
Disease duration (min, max, SD) [years] 12.48	(1,	45,	7.95)
No.	of	patients	with	high	education	(%) 171	(53.1)
Patients	with	fatigue	(%) 168	(52.2)
Patients	with	depression	(%) 87 (27.0)
Patients	with	cognitive	impairment	(%) 164	(50.9)
No. of patients enrolled 322
Note: All of the variables' values are shown in mean.
Abbreviations: EDSS, Expanded Disability Status Scale Score; max, max‐
imum; min, minimum; SD, standard deviation.
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and fatigue were found to have the most ubiquitous and robust ef‐
fect on any given subdivision of the HRQoL composite.
Of	 all	 the	 examined	 variables,	 only	 depression	 and	 fatigue	 in	
general were the sole aspects to have a clinically meaningful (VIP 
score > 1), negative influence on all the 14 measured subscales of 
a patient's perceived HRQoL. Fatigue in general had the strongest 
influence in all of the subscales assessed; however, all of its subsets 
(cognitive, physical, and social fatigue were included, every other 
type of fatigue had been excluded) had a significant impact as well 
on most of the subscales, with the most prominent being physical fa‐
tigue, followed by cognitive, and social fatigue. Physical fatigue had a 
major negative impact on all 14 subscales when evaluating the whole 
cohort as well as when stratified by sexes. Social and cognitive fa‐
tigue had a significant negative influence on all subscales when as‐
sessing the whole cohort; however, when subgrouped by sexes they 
did not reach the threshold in a few subscales. Social fatigue did not 
reach the threshold (VIP score < 1) in the physical health domain 
for men, and in the sexual function for women. Cognitive fatigue 
fell short of being a significant predictor for the change in health, 
emotional well‐being, overall quality of life, satisfaction with sexual 
function, and social function domains for men, yet it remained a sig‐
nificant influencing factor on all subscales for women.
Age, education, and EDSS had an impact only on 3, 1, and 2 sub‐
scales, respectively, while disease duration and CI were not found to 
be a meaningful predictor in any of the subscales. Age had a nega‐
tive effect on the sexual function, satisfaction with sexual function, 
and physical health dimensions. Having high education made a sta‐
tistically significant effect on only one, the social function subscale. 
Patients with more than 12 years of education evaluated their social 
life to be negatively affected by the disease. A higher EDSS score 
has been found to negatively influence participation restriction and 
role limitation among persons with MS in the physical domain. In the 
emotional domain, the patient's physical health had no impact, only 
fatigue and depression had an impact on one's role limitation due 
to emotional problems. With regard to the variables affecting a pa‐
tient's emotional well‐being, fatigue and depression were found to 
be the only ones with significant effect. In all other domains where 
both fatigue and depression had a significant effect, the two of them 
had a similar share of the cumulative impact. In this case, however, 
fatigue's impact was marginal, only depression had an effect as pow‐
erful as seen in the other subscales. With respect to the pain, energy, 
and health perception dimensions, similarly to the majority of the 
other subscales, only depression and fatigue had a significant effect.
When the sexes were compared, of all the aspects examined, de‐
pression and fatigue were the only variables to have a major impact 
on all of the 14 examined domains of HRQoL (VIP > 1) for both men 
and women.
Yet, on 10 of the domains, differences were found between the 
sexes. In case of men, in addition to fatigue and depression, at least 
one other determinant was found to have a negative effect on the 
HRQoL in 9 domains, while in case of the women such was found 
only in two domains. Cognitive impairment for men was a negative 
contributor on the overall quality of life, role limitation due to emo‐
tional problems, sexual functions, and the satisfaction with sexual 
functions domain. In the case of male patients, a higher EDSS score 
had negatively affected the health perceptions dimension of self‐
reported HRQoL. For both sexes, the EDSS score was a negative 
determinant for the physical health (weaker contributor for women 
than for men) and physical role limitations subscales. Age was an 
additional clinical predictor for the change in health, physical health 
dimensions for men and for the sexual functions, and satisfaction 
with sexual functions subscale for women. Men who had studied for 
at least 13 years felt that their HRQoL was also affected by a decline 
in their social function (Table 3).
4  | DISCUSSION
In our study, we evaluated the possible predicting factors of HRQoL 
in	a	large,	homogenous	population	of	MS	patients.	Our	model‐free	
analysis indicated that the most significant contributor to quality of 
life is depression and fatigue. Besides these symptoms, specific sub‐
scales	of	MSQ54	were	driven—to	a	much	lesser	extent—primarily	by	
age, EDSS, and education. Furthermore, for men and women, differ‐
ent contributors were observed to influence the HRQoL, and with 
different level of influence.
TA B L E  2   Comparison of the clinical and sociodemographic data of the different sexes
 Men Women Difference (p value) F value
Mean age at enrollment (min, max, SD) 
[years]
41.34 (22.0, 68.0, 12.10) 43.71 (21.0, 69.0, 11.72) .096 2.781
Mean EDSS score (min, max, SD) [points] 2.16	(0.0,	6.5,	1.73) 1.85	(0.0,	6.5,	1.48) .097 0.000
Disease duration ( min, max, SD) [years] 12.48	(1.0,	45.0,	8.74) 12.48	(1.0,	41.0,	7.57) .997 2.768
No.	of	patient	with	high	education	(%) 56	(54.9) 115	(52.3) .661 Not applicable
Patients	with	fatigue	(%) 50	(49.0) 118	(53.6) .473 Not applicable
Patients	with	depression	(%) 25	(24.5) 62 (28.2) .590 Not applicable
Patients	with	cognitive	impairment	(%) 65	(63.7) 99	(45.0) .002 Not applicable
No. of patients 102 220 Not applicable Not applicable
Note: All of the variables' values are shown in mean.
Abbreviations: EDSS, Expanded Disability Status Scale Score; max, maximum; min, minimum; SD, standard deviation.
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Assessing and analyzing the HRQoL of PwMS is a demanding 
task, as it is a complex—and by nature—a subjective concept. Most 
tools used for its evaluation are based on self‐report, therefore the 
results, despite being quantified measures, often remain a question 
to interpretation. Furthermore, significant deviation can be seen in 
results in the literature when psychopathologic symptoms are exam‐
ined because of the different tools (with different length, depth or 
primary focus) used. Additionally, assessing the HRQoL of a patient 
only at a given point of time or once during a long(er) follow‐up pe‐
riod is not satisfactory, because possible determinants can change 
over time. Despite these issues, focusing on and addressing a possi‐
ble decline the subjective QoL of the patients—in particular regard to 
the medically alterable and measurable aspects—should be a highly 
important medical goal.
Among the many possible and most often investigated pre‐
dictors of quality of life, we examined clinical disability, cognitive 
dysfunction, fatigue, and depression. While EDSS is not a perfect 
measure of disability, in the range what we have examined (EDSS: 
0–6.5	points),	it	is	nearly	linear	and	correlates	well	with	the	patient's	
physical state. For the evaluation of cognitive impairment, we used 
the BICAMS test, an easy and rapidly administrable test in the ev‐
eryday hospital setting, which is being validated to swiftly increasing 
amount of languages, possibly becoming the gold standard screening 
tool to assess a patient's cognitive capabilities, meanwhile covering 
the most commonly affected cognitive domains in PwMS (Corfield 
and Langdon, 2018). Fatigue and depression were assessed by one 
of the most ubiquitous screening tools in use the FIS and BDI ques‐
tionnaires, respectively.
The	prevalence	of	depression	(27.0%),	fatigue	(52.2%),	CI	(50.9%)	
in our cohort was in line the literature (Ben Ari Shevil et al., 2014; 
Chiaravalloti & DeLuca, 2008). With more than 300 patients as‐
sessed, the sample size made it possible to stratify between sexes, 
we confirmed our previous and other results regarding the differ‐
ence	of	CI's	prevalence	between	men	and	women	(Patti	et	al.,	2015;	
Sandi et al., 2017).
Regarding the combined results of men and women, our results 
are in agreement with recent studies to a great extent; however, 
some differences are present. Depression and fatigue are by far 
the leading predictors of perceived HRQoL in all domains (Benedict 
et	 al.,	 2005;	 Fuvesi	 et	 al.,	 2010).	Other	 factors	were	 restricted	 to	
one or two domains only; EDSS to the physical aspects, educational 
status to the social domain. Surprisingly, CI—in general—appears to 
be a minor predictor. Current results on this topic are controversial. 
Many studies showed cognitive impairment to be a primary deter‐
minant of patients' HRQoL, on the other hand, some studies relying 
on self‐reported HRQoL measures did not find CI to be a signifi‐
cant factor (Miller & Allen, 2010; Mitchell, Benito‐Leon, Gonzalez, 
&	Rivera‐Navarro,	 2005).	 The	 reason	 behind	 the	 inconsistency	 of	
these	results	is	multifactorial.	One	possible	reason	is	that	CI	affects	
the vocational status, thus these patients are unable to report their 
problems	sufficiently	(Benedict	et	al.,	2005).	Another	reason	might	
be that patients with serious CI many times are unaware of their 
deficit, sometimes even affected by euphoria and moria, which make  
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their self‐reports unrealistic (Benedict, Priore, Miller, Munschauer, & 
Jacobs, 2001; Benedict et al., 2004). As was concluded by Benedict 
et al., CI seems to be mainly predictive of what PwMS are actually 
capable of doing, rather what they are able to report (Benedict et 
al.,	2005).	Yet	another	reason	for	cognitive	 impairment's	minor	re‐
lationship with our cohort's HRQoL might be the patients' cognitive 
reserve capacity. Higher levels of active and passive cognitive re‐
serve capacity have been shown to be associated with lower levels 
of perceived disability, higher levels of functional health, and higher 
levels of well‐being in patient‐reported outcome surveys (Schwartz, 
Snook, Quaranto, Benedict, & Vollmer, 2013).
As for the gender‐specific impact of MS on the patients' HRQoL, 
the literature is scarce. Men were found to perceive their HRQoL 
significantly worse than women especially in the physical and social 
functioning and vitality domains (Casetta et al., 2009). It was also 
shown that male patients face a worse prognosis in general com‐
pared with women (Greer & McCombe, 2011; Zaffaroni & Ghezzi, 
2000). In addition, prospective studies have found that a worse 
HRQoL can be a significant predictor for the change in the patients' 
disability status (Nortvedt, Riise, Myhr, & Nyland, 2000).
None of these studies have investigated whether there is a dif‐
ference between the factors influencing HRQoL in different sexes 
though. In the current literature, information about gender's effect 
on the HRQoL is scarce, ours is among the first studies to show a 
difference between the sexes regarding the factors that influence 
HRQoL in PwMS. As for men, their physical status and their age—
which are two naturally intertwining aspects of one's physical de‐
cline over the years, hastened by MS—had a more profound and 
powerful impact on more subscales than it did for women. An expla‐
nation for this could be how western societies still attribute great im‐
portance to the role of physical disability, and how a person's “value” 
with a visible physical disability is perceived. Despite the rapid ad‐
vancement of IT technology, many jobs have emerged that require 
no classical physical endurance and vitality, our culture still places 
great value upon appearances, how a person's stature emanates ef‐
ficiency and capability. Living with a visible physical disability could 
induce a sensation of failure to meet social standards and to cease to 
be the provider in a household, which could be a more serious prob‐
lem for men than women (Barnwell & Kavanagh, 1997; Duval, 1984).
We hypothesize that the reason cognitive impairment solely 
influenced the HRQoL of men but not women is due to the fact 
that CI's prevalence is much higher in men, and thus its impact has 
reached a threshold where its burden becomes a significant factor 
(Sandi et al., 2017). The presence of CI makes an MS patient more 
likely to get divorced, thus self‐reportedly he feels a significant de‐
cline in his sexual life (Hakim et al., 2000). Also as discussed before, 
a person with CI is not able to pinpoint exactly the problem present 
(and thus generally has a better overall HRQoL questionnaire), but 
to an extent feels that something has changed and, as we demon‐
strated CI can have a negative impact on one's overall quality of life, 
without influencing the different, more exact subscales individually. 
Having spent more time in the educational system predicted worse 
scores on the social HRQoL domain for men, which was expected, 
as it has been shown that people with higher education have bet‐
ter prospects at well‐paying jobs, better work hours, and economic 
prosperity (Weintraub et al., 2011). From this higher social state, a 
sudden fall—may it be real or only perceived—due to a debilitating 
sickness can decrease the HRQoL of a PwMS to a great extent, es‐
pecially for men who are still the wage‐earners in many societies.
5  | CONCLUSION
The concept of HRQoL is far more complex than simply the physical 
impact	as	most	care	models	would	traditionally	relate.	Our	assess‐
ment further underlines this opinion, as we have shown that the less 
evaluated, yet frequently prevalent psychological burdens of the dis‐
ease (particularly depression and fatigue) are the main determinants 
of the self‐reported well‐being of PwMS. We have confirmed other 
studies' findings (Yalachkov et al., 2019), that fatigue and depression 
are the main determinants of MS patients' HRQoL not only at disease 
onset, as previously shown (Nourbakhsh, Julian, & Waubant, 2016; 
when one would expect a patient to have a drop in their HRQoL, 
and become burdened with depression, after being diagnosed with 
a lifelong, degenerative disease), but years after the diagnosis as 
well. Therefore the evaluation and treatment of PwMS should be 
conducted on a much broader spectrum than regular physical and 
MRI examinations, even in the youngest population (Rainone et al., 
2017), a pre‐emptive approach is proposed. These findings invoke 
the need for the regular assessment of depression, fatigue, cogni‐
tion, and other psychopathological aspects with a multidimensional, 
quantitative approach.
Also, ours is one of the first studies in the literature to show that 
different burdens influence the HRQoL of men and women, and 
with different strength. This further supports the need for the com‐
plex and personalized care for these patients, furthermore, regular 
psychopathological assessments and periodic feedback regarding a 
patient's HRQoL are urged especially since different determinants 
influence the HRQoL of men and women. It also proves the need for 
involvement of psychological and psychiatric specialists and team‐
work for the proper management of patients burdened by MS, as 
many of these symptoms can be ameliorated and managed by not 
only a psychopharmacological, but by a psychotherapeutic approach 
as well.
6  | STUDY LIMITATIONS
One	of	the	limitations	of	this	study	was	the	lack	of	assessment	of	
patient's anxiety, which has been shown to be a major contributing 
factor to the HRQoL of PwMS (Janssens et al., 2003; Salehpoor, 
Rezaei, & Hosseininezhad, 2014). Another limitation is the ab‐
sence of administration of detailed neuropsychological tests and 
evaluation of the active and passive cognitive reserve capacity of 
our patients, which was beyond the scope and primary focus of 
this article, but is nonetheless a crucial element in the long‐term 
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treatment of MS patients living with cognitive impairment. The 
strong points of our paper include the relatively big cohort, the 
wide range of variables assessed and the strong statistical model 
measuring every examined variable's impact on the HRQoL of our 
patients and novel data on the difference of predictors constitut‐
ing the HRQoL of men and women.
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